Geron competitors

Geron Competitors include Heat Biologics, Cleveland BioLabs, Immune Design and Aptevo Therapeutics.
Add company...
Geron
Geron
Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Heat Biologics
Heat Biologics
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.
Cleveland BioLabs
Cleveland BioLabs
CBLI’s mission is to develop and commercialize innovative drugs to treat cancer and protect healthy tissues from radiation, chemotherapy or ischemic conditions.
Immune Design
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
Aptevo Therapeutics
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Founding Date
Founding Date
1990
Founding Date
2008
Founding Date
2003
Founding Date
2008
Founding Date
2016
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Menlo Park, US HQ
Canton, US
Locations
Durham, US HQ
Locations
Buffalo, US HQ
Locations
Seattle, US HQ
South San Francisco, US
Locations
Seattle, US HQ
Employees
Employees
15
Employees
19
Employees
12
Employees
55
Employees
121
Valuation ($)
Valuation ($)
316.9 m
Valuation ($)
41.2 m
Valuation ($)
18.3 m
Valuation ($)
282.9 m
Valuation ($)
36.3 m

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$2.2m (FY, 2018)
Revenue (est.)
$23.1m (FY, 2018)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$1.4m (FY, 2018)
Cost of goods
$11.2m (FY, 2018)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$761k (FY, 2018)
Gross profit
$11.9m (FY, 2018)
Net income
Net income
($27m) (FY, 2018)
Net income
($12.4m) (FY, 2017)
Net income
($3.7m) (FY, 2018)
Net income
($54.8m) (FY, 2018)
Net income
($53.7m) (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 96.7m
Total funding raised
N/A
Total funding raised
$ 12.2m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Heat Biologics
HQ
Durham, US
Employees
19

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

View company
Cleveland BioLabs
HQ
Buffalo, US
Employees
12

CBLI’s mission is to develop and commercialize innovative drugs to treat cancer and protect healthy tissues from radiation, chemotherapy or ischemic conditions.

View company
Immune Design
HQ
Seattle, US
Employees
55

Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.

View company
Aptevo Therapeutics
HQ
Seattle, US
Employees
121

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.

View company